$1.10
▼ -0.9% Today
as of Sep 4, 16:47 ET
Last 30 days
Recent Press Releases & News
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
Creative Medical Receives U.S. Patent Allowance for Exosome-Based Type 1 Diabetes Immunotherapy
Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
Overview
52-week range
$0.62
$6.25
9% of range
Avg surprise (last 3)
-11.1%
Avg reaction (last 2)
+1.6%
100% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.41 | — | — | — | — | financials |
| Fri May 8, 2026 | Mar/2026 | $-0.38 | $-0.39 | +2.6% | +54.2% | +0.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.48 | — | — | — | — | financials |
| Fri Aug 8, 2025 | Jun/2025 | $-0.48 | $-0.63 | +23.8% | — | — | earnings |
| Fri May 9, 2025 | Mar/2025 | $-0.83 | $-0.52 | -59.6% | — | +2.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.75 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.11 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.73 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | $0 | $0 | $3,000 | — | $0 |
| Cost of revenue | $0 | $0 | — | $0 | $0 | $1,200 | — | $0 |
| Gross profit | $0 | $0 | — | $0 | $0 | $1,800 | — | $0 |
| Operating income | $-2M | $-1M | — | $-1M | $-1M | $-2M | — | $-1M |
| Net income | $-2M | $-1M | — | $-1M | $-1M | $-2M | — | $-1M |
| EPS (diluted) | $-0.41 | $-0.38 | — | $-0.48 | $-0.48 | $-0.83 | — | $-0.75 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Inventory | $125,000 | $125,000 | $0 | $994 | $994 | $994 | $2,194 | $3,394 |
| Total current assets | $9M | $6M | $7M | $5M | $7M | $8M | $6M | $6M |
| Total assets | $9M | $6M | $8M | $6M | $7M | $8M | $7M | $7M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $698,595 | $307,649 | $284,880 | $261,353 | $277,644 | $286,387 | $327,644 | $330,908 |
| Total equity | $9M | $6M | $8M | $6M | $7M | $8M | $6M | $7M |
Implied volatility — last 90 days
No IV snapshots yet for CELZ.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.